Inspire Investing LLC Has $280,000 Stake in Bio-Rad Laboratories, Inc. $BIO

Inspire Investing LLC decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,160 shares of the medical research company’s stock after selling 121 shares during the period. Inspire Investing LLC’s holdings in Bio-Rad Laboratories were worth $280,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of BIO. Quarry LP bought a new stake in shares of Bio-Rad Laboratories in the first quarter worth $29,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 104 shares in the last quarter. UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 89.8% in the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after buying an additional 79 shares during the last quarter. Headlands Technologies LLC lifted its position in Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after buying an additional 139 shares in the last quarter. Finally, Twin Tree Management LP bought a new stake in Bio-Rad Laboratories during the 1st quarter worth about $87,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

BIO has been the topic of several analyst reports. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, August 22nd. Royal Bank Of Canada boosted their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Bio-Rad Laboratories in a report on Tuesday. Wells Fargo & Company raised their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $333.50.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $310.97 on Friday. The company’s 50-day moving average is $289.99 and its 200-day moving average is $258.56. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The firm has a market capitalization of $8.42 billion, a PE ratio of 26.51 and a beta of 0.97. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The business had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. Bio-Rad Laboratories’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.